Latest Breaking News On - France newsfile corp - Page 4 : comparemela.com

Renesas Extends Tender Offer for Proposed Acquisition of Sequans

Renesas Electronics Corporation and Sequans Communications S.A. today announced that Renesas has extended the expiration date of its tender offer to acquire all of the outstanding ordinary shares.

France generalNew yorkUnited statesHong kongUnited kingdomKimberly tassinAkiko ishiyamaKim rogersRenesas electronics europe gmbExchange commissionRenesas electronics corporationFrance newsfile corpNeedham companyHerrington sutcliffeSequans communications saGoodwin procter

Sequans Communications: Renesas Extends Tender Offer for Proposed Acquisition of Sequans

Sequans Communications: Renesas Extends Tender Offer for Proposed Acquisition of Sequans
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

South koreaUnited statesUnited kingdomHong kongNew yorkFrance generalAkiko ishiyamaStefan klotterKimberly tassinKim rogersNeedham companySequans communicationsExchange commissionFrance newsfile corpHerrington sutcliffeSequans communications sa

Renesas Extends Tender Offer for Proposed Acquisition of Sequans

Renesas Electronics Corporation and Sequans Communications S.A. today announced that Renesas has extended the expiration date of its tender offer to acquire all of the outstanding ordinary shares.

United statesFrance generalSouth koreaHong kongNew yorkUnited kingdomKim rogersAkiko ishiyamaKimberly tassinRenesas electronics corporationExchange commissionNeedham companyHerrington sutcliffeGoodwin procterRenesas electronics europe gmbFrance newsfile corp

Kiora Pharmaceuticals, Inc : Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront

Kiora Pharmaceuticals, Inc : Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesClermont ferrandBrian stremStefan klotterFrance newsfile corpKiora pharmaceuticalsKiora pharmaceuticals incAmerican academy of ophthalmologyOpen innovationRetinitis pigmentosaAmerican academyRetinal ganglion cellsInvestor relationsNorth africaSouth americaPrivate securities litigation reform act

Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties

Kiora Pharmaceuticals, Inc. , a clinical-stage biotech company developing treatments for orphan retinal diseases, today announced that it has entered a strategic development and commercialization.

United statesClermont ferrandBrian stremAmerican academy of ophthalmologyKiora pharmaceuticals incKiora pharmaceuticalsFrance newsfile corpOpen innovationRetinitis pigmentosaAmerican academyRetinal ganglion cellsInvestor relationsNorth africaSouth americaPrivate securities litigation reform actAnnual report